Role of bisphosphonates in the management of postmenopausal osteoporosis: An update on recent safety anxieties

Menopause International

Volumn 17, Issue 2, 2011, Pages 66-72

  Hollick, Rosemary J ^a   Reid, David M ^b  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

adverse effects; bisphosphonates; fracture prediction; hormone replacement therapy; Postmenopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; ANTIHISTAMINIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; IBANDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; RISEDRONIC ACID; ZOLEDRONIC ACID;

ANGIONEUROTIC EDEMA; BLURRED VISION; BONE DENSITY; BONE METASTASIS; BRAIN ISCHEMIA; CLINICAL PRACTICE; CONJUNCTIVITIS; CREATININE CLEARANCE; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EPIDERMOLYSIS; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; ESOPHAGUS DISEASE; EYE DISEASE; EYE PAIN; FEMUR SHAFT FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; FLU LIKE SYNDROME; FRACTURE HEALING; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HUMAN; JAW OSTEONECROSIS; KIDNEY DISEASE; MACULOPAPULAR RASH; META ANALYSIS (TOPIC); MUSCULOSKELETAL PAIN; MYELOMA; NAUSEA; PATIENT COMPLIANCE; PHOTOSENSITIVITY; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEVENS JOHNSON SYNDROME; STOMACH EROSION; STOMACH IRRITATION; STOMACH ULCER; TREATMENT DURATION; URTICARIA; UVEITIS; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; DIPHOSPHONATES; ESOPHAGEAL NEOPLASMS; FEMALE; FEMORAL FRACTURES; HIP FRACTURES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 79959481579     PISSN: 17540453     EISSN: 17540461     Source Type: Journal    
DOI: 10.1258/mi.2011.011014     Document Type: Review

References (53)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Consensus panel on osteoporosis prevention. JAMA 2001; 285: 785–95
2. National Institute for Health and Clinical Excellence (NICE). TA160 Osteoporosis – primary prevention: guidance. See http://www.guidance.nice.org.uk/TA160/Guidance/pdf/English ( last checked 17 March 2011)
3. Burge RT, Worley D, Johansen A, Bhattacharyya S. The cost of osteoporotic fractures in the UK: Projections for 2000–2020. J Med Econ 2001; 4: 51–62
4. Watson J, Wise L, Green J. Prescribing of hormone replacement therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol 2007; 63: 843–49
5. Chaiamnuay S, Saag KG. Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates? Rev Endocr Metab Disord 2006; 7: 101–12
6. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley J. Once-yearly Zoledronic acid for treatment of postmenopausal osteoporosis. N Eng J Med 2007; 356: 1809–22
7. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C. Zoledronic acid and clinical fractures and mortality after hip fracture. N Eng J Med 2007; 357: 1799–809
8. Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endcrinol Metab 2010; 95: 1174–81
9. Neives JW, Bilezikian JP, Lane JM,, et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 2010; 21: 399–408
10. Shane E, Burr D, Ebeling PR,, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for bone and mineral research. J Bone Miner Res 2010; 25: 2267–94
11. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: A Register-Based National Cohort Study. J Bone Miner Res 2009; 24: 1095–102
12. Abrahamsen B. Bisphosphonate adverse effects, lessons from large databases. Curr Opin Rheumatol 2010; 22: 404–409
13. Black DM, Kelly MP, Genant HK,, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010; 362: 1761–71
14. Park-Wyllie LY, Mamdani MM, Juurlink DN,, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011; 305: 783–89
15. Dell R, Greene D, Ott S,, et al. A Retrospective Analysis of all Atypical Femur Fractures Seen in a Large California HMO from the Years 2007 to 2009. ASBMR 2010 Annual Meeting, Toronto, Canada
16. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Eng J Med 2007; 356: 1895–96
17. Karam R, Camm J, McClung M. Yearly Zoledronic acid in postmenopausal osteoporosis. N Eng J Med 2007; 357: 712–713
18. FDA. Update of Safety Review Follow-up to the October 1, 2007 Early Communication about the Ongoing Safety Review of Bisphosphonates. See http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm ( last checked 23 March 2011)
19. Mak A, Cheung MWL, Ho RC-M, Cheak AA, Lau CS. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMS Musculoskeletal Disorders 2009; 10: 113
20. Sorensen HT, Christensen S, Mehnert F,, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 2008; 336: 813–816
21. Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: A self-controlled case-series safety analysis. PLoS One 2009; 4: e4720
22. Abrahamsen B, Eiken P, Brixen K. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med 2009; 265: 581–92
23. Bunch TJ, Anderson JL, May HT,, et al. Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 2009; 103: 824–828
24. Tanko LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 2005; 20: 1912–20
25. Pazianas M, Compston J, Huang CL-H. Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res 2010; 25: 2–10
26. Reid DM. Handbook of Osteoporosis. London: Springer Healthcare, 2010
27. Graham DY. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci 2002; 47: 1665–78
28. Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 2006; 119: 12S–17S
29. Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L. Gastric and esophagus events before and during treatment of osteoporosis. Calcif Tissue Int 2010; 86: 110–115
30. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Eng J Med 2009; 360: 89–90
31. Abrahamsen B, Eiken P, Eastell R. More on reports of esophageal cancer with oral bisphosphonate use. N Eng J Med 2009; 360: 1789–90
32. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010; 304: 657–63
33. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of the oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010; 341: c4444
34. MHRA. Important safety information for bisphosphonates issued by the MHRA, September 2010. See http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-A-F/Bisphosphonates/index.htm#l22 ( last checked 17 March 2011)
35. Reid IR. Osteonecrosis of the jaw: who gets it, and why? Bone 2009; 44: 4–10
36. Solomon DH, Rekedal L, Cadarette SM. Osteoporosis treatments and adverse effects. Curr Opin Rheumatol 2009; 21: 363–368
37. Reid DM. Update on the use of zoledronic acid in the management of osteoporosis. Curr Osteoporos Rep 2010; 8: 145–50
38. Kunzmann V, Bauer E, Wilhelm M. γ/δ T-cell stimulation by pamidronate. N Eng J Med 1999; 340: 737–738
39. Thompson K, Keech F, McLernon DJ,, et al. Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women. Bone 2011 Available online 22 Nov 2010. DOI:10.1016/j.bone.2010.10.177
40. Fraunfelder FW, Fraunfelder FT. Bisphosphonates and ocular inflammation. N Eng J Med 2003; 348: 1187–8
41. Musette P, Brandi ML, Cacoub P, Kaufman JM, Rizzoli R, Reginster J-Y. Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporos Int 2010; 21: 723–32
42. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX TM and the assessment of fracture probablity in men and women from the UK. Osteoporos Int 2008; 19: 385–97
43. Compston J, Cooper A, Cooper C,, et al. on behalf of the National Osteoporosis Guideline Group (NOGG). Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. See http://www.shef.ac.uk/NOGG/NOGG_Pocket_Guide_for_Healthcare_Professionals.pdf ( last checked 17 March 2011)
44. Bone HG, Hosking D, Devogelaer J-P,, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Eng J Med 2004; 350: 89–99
45. Mellstrom DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75: 462–468
46. Black DM, Schwartz AV, Ensrud KE,, et al. Effects of continuing or stopping Alendronate after 5 years of treatment. The fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 2006; 296: 2927–38
47. Watts NB, Chines A, Olszynski WP,, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008; 19: 365–72
48. Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001; 285: 2891–7
49. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principle results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–33
50. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–27
51. Wasserheil-Smoller S, Hendrix SL, Limacher M,, et al. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. JAMA 2003; 289: 2673–84
52. CMDh. Core SPC For Hormone Replacement Therapy Products, December 2009. See http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Product_Information/Core_SPC_PL/Core_SPCs/CMDh_131_2003_Rev3_Clean_2010_01_Core_SmPC_for_HRT.pdf ( last checked 17 March 2011)
53. National Osteoporosis Society. National Osteoporosis Society Policy on Hormone Replacement for the Treatment and Prevention of Osteoporosis. See http://www.nos.org.uk/document.doc?id=676 ( last checked 17 March 2011)